Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vectron T500 is an indoor residual spray (IRS) insecticide developed by Mitsui Chemicals Crop & Life Solutions in collaboration with the Innovative Vector Control Consortium (IVCC) for the control of malaria-carrying mosquitoes. Its active ingredient is broflanilide, a meta-diamide insecticide that represents a novel chemical class with a unique mode of action. It acts as an antagonist at insect gamma-aminobutyric acid (GABA) receptors, blocking inhibitory neurotransmission and leading to hyperexcitation and death of the insect. The product is specifically designed to combat pyrethroid-resistant malaria vectors, such as Anopheles gambiae, and has received WHO prequalification. It is formulated as a wettable powder and demonstrates long-lasting residual efficacy on various surfaces for 6 to 18 months.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vectron T500.